Búsqueda | Biblioteca Virtual en Salud

1.

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Rivera, Victor M; Jeffery, Douglas R; Weinstock-Guttman, Bianca; Bock, Daena; Dangond, Fernando.

BMC Neurol ; 13: 80, 2013 Jul 11.

Artículo en Inglés | MEDLINE | ID: mdl-23841877

2.

Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies.

Hartung, Hans-Peter; Kieseier, Bernd; Goodin, Douglas S; Arnason, Barry Gw; Comi, Giancarlo; Cook, Stuart; Filippi, Massimo; Jeffery, Douglas R; Kappos, Ludwig; Bogumil, Timon; Stemper, Brigitte; Sandbrink, Rupert; Nakada, Yukiko; Nakajima, Haruhiko; Schwenke, Susanne; Lehr, Stephan; Heubach, Jürgen; Pohl, Christoph; Reischl, Joachim.

J Neuroinflammation ; 9: 129, 2012 Jun 15.

Artículo en Inglés | MEDLINE | ID: mdl-22703536

3.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Mikol, Daniel D; Barkhof, Frederik; Chang, Peter; Coyle, Patricia K; Jeffery, Douglas R; Schwid, Steven R; Stubinski, Bettina; Uitdehaag, Bernard M J.

Lancet Neurol ; 7(10): 903-14, 2008 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-18789766

4.

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.

Jeffery, Douglas R; Rammohan, Kottil W; Hawker, Kathleen; Fox, Edward.

Expert Rev Neurother ; 16(1): 31-44, 2016.

Artículo en Inglés | MEDLINE | ID: mdl-26587577

5.

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Jeffery, Douglas R; Di Cantogno, Elisabetta Verdun; Ritter, Shannon; Meier, Daniela Piani; Radue, Ernst-Wilhelm; Camu, William.

J Neurol ; 263(2): 299-305, 2016 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-26568562

6.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Schippling, Sven; O'Connor, Paul; Knappertz, Volker; Pohl, Christoph; Bogumil, Timon; Suarez, Gustavo; Cook, Stuart; Filippi, Massimo; Hartung, Hans-Peter; Comi, Giancarlo; Jeffery, Douglas R; Kappos, Ludwig; Goodin, Douglas S; Arnason, Barry.

J Neurol ; 263(7): 1418-26, 2016 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-27177997

7.

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.

Fitzgerald, Kathryn C; Munger, Kassandra L; Köchert, Karl; Arnason, Barry G W; Comi, Giancarlo; Cook, Stuart; Goodin, Douglas S; Filippi, Massimo; Hartung, Hans-Peter; Jeffery, Douglas R; O'Connor, Paul; Suarez, Gustavo; Sandbrink, Rupert; Kappos, Ludwig; Pohl, Christoph; Ascherio, Alberto.

JAMA Neurol ; 72(12): 1458-65, 2015 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-26458124

8.

Natalizumab for relapsing multiple sclerosis.

Jeffery, Douglas R.

N Engl J Med ; 354(22): 2387-9; author reply 2387-9, 2006 Jun 01.

Artículo en Inglés | MEDLINE | ID: mdl-16742008

9.

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis.

Jeffery, Douglas R.

J Neurol Sci ; 197(1-2): 1-8, 2002 May 15.

Artículo en Inglés | MEDLINE | ID: mdl-11997060

10.

The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.

Jeffery, Douglas R.

J Neurol Sci ; 223(1): 41-6, 2004 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-15261559

11.

Treatment of Marburg variant multiple sclerosis with mitoxantrone.

Jeffery, Douglas R; Lefkowitz, David S; Crittenden, Jeffrey P.

J Neuroimaging ; 14(1): 58-62, 2004 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-14748210

12.

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.

Jeffery, Douglas R.

Ther Adv Chronic Dis ; 4(1): 45-51, 2013 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-23342246

13.

Interleukin 17F level and interferon ß response in patients with multiple sclerosis.

Hartung, Hans-Peter; Steinman, Lawrence; Goodin, Douglas S; Comi, Giancarlo; Cook, Stuart; Filippi, Massimo; O'Connor, Paul; Jeffery, Douglas R; Kappos, Ludwig; Axtell, Robert; Knappertz, Volker; Bogumil, Timon; Schwenke, Susanne; Croze, Ed; Sandbrink, Rupert; Pohl, Christopher.

JAMA Neurol ; 70(8): 1017-21, 2013 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-23732754

14.

The changing face of multiple sclerosis clinical trial populations.

Uitdehaag, Bernard M J; Barkhof, Frederik; Coyle, Patricia K; Gardner, Jason D; Jeffery, Douglas R; Mikol, Daniel D.

Curr Med Res Opin ; 27(8): 1529-37, 2011 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-21671851

15.

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery, Douglas R; Markowitz, Clyde E; Reder, Anthony T; Weinstock-Guttman, Bianca; Tobias, Kathy.

Expert Rev Neurother ; 11(2): 165-83, 2011 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-21158700

16.

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

Cree, Bruce A C; Stuart, William H; Tornatore, Carlo S; Jeffery, Douglas R; Pace, Amy L; Cha, Choon H.

Arch Neurol ; 68(4): 464-8, 2011 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-21482925

17.

Chemotherapeutics in the treatment of multiple sclerosis.

Kieseier, Bernd C; Jeffery, Douglas R.

Ther Adv Neurol Disord ; 3(5): 277-91, 2010 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-21179618

18.

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.

Jeffery, Douglas R; Pharr, Emily Poole.

Core Evid ; 5: 107-12, 2010.

Artículo en Inglés | MEDLINE | ID: mdl-21468366

19.

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.

Kaiser, Claudia C; Shukla, Dinesh K; Stebbins, Glenn T; Skias, Demetrios D; Jeffery, Douglas R; Stefoski, Dusan; Katsamakis, George; Feinstein, Douglas L.

J Neuroimmunol ; 211(1-2): 124-30, 2009 Jun 25.

Artículo en Inglés | MEDLINE | ID: mdl-19446890

20.

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.

Jeffery, Douglas R; Chepuri, Neraj; Durden, David; Burdette, Jonathon.

Mult Scler ; 11(3): 296-301, 2005 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-15957510

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies.

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.

Natalizumab for relapsing multiple sclerosis.

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis.

The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.

Treatment of Marburg variant multiple sclerosis with mitoxantrone.

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy.

Interleukin 17F level and interferon ß response in patients with multiple sclerosis.

The changing face of multiple sclerosis clinical trial populations.

Fingolimod for the treatment of relapsing multiple sclerosis.

Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.

Chemotherapeutics in the treatment of multiple sclerosis.

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.